| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Development Services Per Exclusive Agreement Year One | 4.0 | | | | | | | |
| National Health Plan Statement of Work Agreement | 1.8 | | | | | | | |
| Other | 21.9 | | | | | | | |
| Total revenues | 27.7 | 20.5 | 7.6 | 7.6 | 7.4 | 5.2 | 2.8 | 0.8 |
| Revenue growth | 34.8% | 170.8% | 0.2% | 2.2% | 43.0% | 84.4% | 240.6% | 1513.7% |
| Cost of goods sold | 18.0 | 16.6 | 5.1 | 5.0 | 5.6 | 3.9 | 3.4 | 1.7 |
| Gross profit | 9.7 | 4.0 | 2.5 | 2.6 | 1.8 | 1.3 | -0.6 | -0.9 |
| Gross margin | 34.9% | 19.3% | 33.2% | 34.4% | 23.9% | 25.4% | -20.0% | -103.9% |
| Selling, general and administrative [+] | 46.8 | 63.2 | 28.0 | 16.6 | 15.8 | 12.4 | 8.1 | 4.3 |
| Sales and marketing | 30.3 | 39.7 | 15.2 | 11.1 | 10.3 | 7.7 | 4.7 | 1.3 |
| General and administrative | 16.5 | 23.5 | 12.8 | 5.5 | 5.5 | 4.7 | 3.4 | 2.9 |
| Research and development | 19.6 | 17.2 | 4.4 | 3.7 | 3.7 | 3.3 | 2.2 | 2.6 |
| Other operating expenses | | | | | | | 0.3 | -15.4 |
| EBITDA [+] | -52.1 | -72.0 | -29.7 | -17.5 | -17.5 | -14.2 | -10.7 | 8.0 |
| EBITDA growth | -27.7% | 142.4% | 69.6% | 0.2% | 22.9% | 32.8% | -233.4% | -177.8% |
| EBITDA margin | -188.4% | -351.2% | -392.2% | -231.8% | -236.4% | -275.1% | -382.2% | 976.1% |
| Depreciation | 0.4 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.4 | 0.3 |
| EBITA | -52.4 | -72.3 | -29.9 | -17.7 | -17.7 | -14.4 | -11.1 | 7.7 |
| EBITA margin | -189.6% | -352.6% | -394.7% | -234.2% | -239.2% | -278.9% | -396.0% | 935.4% |
| Amortization of intangibles | 4.4 | 4.2 | | | | | | |
| EBIT [+] | -56.8 | -76.5 | -29.9 | -17.7 | -17.7 | -14.4 | -11.1 | 7.7 |
| EBIT growth | -25.7% | 155.8% | 68.9% | 0.1% | 22.7% | 29.9% | -244.2% | -170.8% |
| EBIT margin | -205.4% | -372.9% | -394.7% | -234.2% | -239.2% | -278.9% | -396.0% | 935.4% |
| Interest expense, net [+] | -0.5 | 0.0 | -0.1 | 0.0 | | | | |
| Interest expense | 1.9 | | | | | | | |
| Interest income | 0.5 | 0.0 | 0.1 | 0.0 | | | | |
| Other income (expense), net [+] | 120.4 | 153.2 | 0.4 | 0.0 | -0.1 | -1.3 | 0.2 | -14.8 |
| Change in fair value of warrants | -1.0 | | | | 0.0 | 1.2 | -0.3 | -0.6 |
| Other | | | | | -0.1 | 0.2 | 0.7 | 0.0 |
| Pre-tax income | 62.2 | 76.7 | -29.4 | -17.7 | -17.8 | -15.7 | -10.9 | -7.1 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -31.5 | -21.8 | -14.3 |
| Tax rate | | | 0.0% | 0.0% | 0.0% | 200.0% | 200.0% | 200.0% |
| Net income | 62.2 | 76.8 | -33.1 | -20.9 | -18.3 | 16.0 | 11.6 | 7.3 |
| Net margin | 224.9% | 374.2% | -436.9% | -276.4% | -247.4% | 309.4% | 414.1% | 886.5% |
| |
| Basic EPS [+] | $2.63 | $4.63 | ($5.55) | ($9.22) | ($15.63) | $1.66 | $2.23 | $3.84 |
| Growth | -43.1% | -183.3% | -39.8% | -41.0% | -1040.6% | -25.5% | -42.0% | 107.8% |
| Diluted EPS [+] | $2.63 | $4.63 | ($5.55) | ($9.22) | ($15.63) | $1.66 | $2.23 | $3.84 |
| Growth | -43.1% | -183.3% | -39.8% | -41.0% | -1040.6% | -25.5% | -42.0% | 107.8% |
| |
| Shares outstanding (basic) [+] | 23.6 | 16.6 | 6.0 | 2.3 | 1.2 | 9.6 | 5.2 | 1.9 |
| Growth | 42.5% | 178.2% | 163.1% | 93.6% | -87.8% | 85.1% | 174.2% | -78.1% |
| Shares outstanding (diluted) [+] | 23.6 | 16.6 | 6.0 | 2.3 | 1.2 | 9.6 | 5.2 | 1.9 |
| Growth | 42.5% | 178.2% | 163.1% | 93.6% | -87.8% | 85.1% | 174.2% | -78.1% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |